FMT Shows Promise for Peanut Allergy in Phase I Trial, Pointing to Bile Acid Role

For someone with a severe peanut allergy, life is a series of small calculations—reading labels, asking questions at restaurants, keeping an epinephrine auto-injector close. In the United States, roughly one in ten adults lives with some form of food allergy, and the stakes are high. A trace amount of peanut protein, less than half a single nut, can trigger a dangerous reaction. Existing treatments like oral immunotherapy can help, but they require ongoing maintenance, and many patients relapse once they stop. A new study from Boston Children's Hospital suggests there may be another path forward, one that runs through the bacteria living in your gut.

Researchers conducted a small Phase I trial with fifteen adults whose allergies were severe enough that they reacted to 100 milligrams of peanut protein or less. The intervention was unusual: oral capsules containing fecal microbiome material—essentially, transplanted gut bacteria from healthy donors. Ten participants received a single dose of thirty-six frozen capsules without any antibiotic preparation. Three of them showed measurable improvement in their peanut tolerance. A second group of five participants received antibiotics first to clear their existing microbiome, then received the FMT capsules. Three of those five also improved. Across the full study, six of the fifteen participants met the efficacy endpoint, and their responses held steady through the four-month follow-up period. Critically, no serious adverse events occurred. No allergic reactions to the transplant itself. No grade 3 or higher complications.

What made this trial significant was not just the clinical result but the mechanism the researchers uncovered. When they examined the immune cells of participants who responded well to FMT, they found a shift toward tolerogenic regulatory T cells—the immune cells that teach the body to accept rather than attack a food. At the same time, type 2 helper T cells, which drive allergic responses, declined. The researchers then took the gut bacteria from successful responders and transferred them into mice bred to be allergic to peanuts. Those mice were protected. When they transferred bacteria from participants who did not respond to treatment, the mice remained allergic. The difference came down to a specific bacterial genus, Bacteroides, and a particular metabolite those bacteria produce: bile acids.

Bile acids are molecules the body uses to digest fat, but they also have an unexpected role in immune regulation. The researchers showed that when Bacteroides bacteria metabolize bile salts—a process controlled by a specific gene—they generate compounds that promote the growth and function of those protective regulatory T cells. When the team deleted that gene from a candidate Bacteroides strain, the protective effect weakened in mice. The chain of causation became clearer: the right bacteria, producing the right metabolites, could nudge the immune system back toward tolerance.

Rima Rachid, director of the Food Allergy Program at Boston Children's Hospital, called it a landmark finding. "This is the first time we've shown that a microbiome-based therapy can improve food allergy in people while also revealing how gut bacteria, their metabolites, and the immune system work together," she said. Talal Chatila, the hospital's director of translational immunology, added that the work opens a path to optimization: understanding the mechanism means researchers can now design better versions of the therapy, potentially using purified bacterial strains rather than whole fecal transplants.

The caveats are real. The trial was small, open-label, and included only adults. The researchers noted an unexpected pattern: five of the six responders were male, compared to only two of the nine nonresponders. That sex bias, unexplained and potentially important, will need investigation in larger studies. The authors themselves emphasized that confirmation is essential, that identifying which patients are most likely to benefit remains an open question, and that the next step may be developing targeted probiotic therapies—designer bacterial formulations that contain only the protective strains without the need for full transplantation.

Rachid is already leading follow-up work. New trials are testing a purified, concentrated microbial formulation in teenagers and exploring whether the approach can be combined with oral immunotherapy, the existing standard treatment. If those studies confirm what this small Phase I trial suggests, the landscape of food allergy treatment could shift. Instead of lifelong avoidance or dependence on immunotherapy, patients might one day receive a course of carefully selected bacteria—a therapy that works not by training the immune system through repeated exposure, but by restoring the gut's natural capacity to teach tolerance.